The American Society of Hematology has highlighted the need for the training of physicians and scientists, basic and clinical research, in hematology. The training program in hematology at the University of Minnesota addresses this concern by providing: 1) inter- and multi-disciplinary research training in five major realms of hematology;2 senior and junior faculty members of both genders as mentors;3) a fusion of research and clinical training for physician and PhD trainees;4) an outstanding resource-filled environment;and 5) the skills for trainees to both survive and thrive in academic medicine. The overarching objective of the training program is to train physicians and scientists for careers in academic medicine and hematology related research. Our program philosophy is to achieve this by carefully balancing sufficient structure to ensure rigor of the trainee experience and programmatic flexibility to accommodate the different needs of trainees. It is our intention to provide trainees with the basic skills that are adaptable to new paradigms of disease, capable of embracing of new technologies, and committed to the highest ethical standards. This post-doctoral training program will allow six trainees at least two years of research experience. This hematology training program, in the tradition of the last 35 years, is confident that future leader of hematology research will matriculate through the University of Minnesota program.

Public Health Relevance

Advanced research training of doctors and scientists focused on blood diseases is essential to finding cures for leukemia or the prevention of fatal blood clots. This training program will prepare hematologists and scientists to develop new scientifically-based treatments and understandings of these diseases to improve the health and safety of patients will blood diseases.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL007062-37
Application #
8423321
Study Section
Special Emphasis Panel (ZHL1-CSR-M (O1))
Program Officer
Chang, Henry
Project Start
1982-07-01
Project End
2017-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
37
Fiscal Year
2013
Total Cost
$425,198
Indirect Cost
$28,326
Name
University of Minnesota Twin Cities
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Goldberg, Michael F; Roeske, Elizabeth K; Ward, Lauren N et al. (2018) Salmonella Persist in Activated Macrophages in T Cell-Sparse Granulomas but Are Contained by Surrounding CXCR3 Ligand-Positioned Th1 Cells. Immunity 49:1090-1102.e7
Don Yun, Hyun; Felices, Martin; Vallera, Daniel A et al. (2018) Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells. Blood Adv 2:1580-1584
Shaban, Nadine M; Shi, Ke; Lauer, Kate V et al. (2018) The Antiviral and Cancer Genomic DNA Deaminase APOBEC3H Is Regulated by an RNA-Mediated Dimerization Mechanism. Mol Cell 69:75-86.e9
Kramer, Ashley C; Blake, Amanda L; Taisto, Mandy E et al. (2017) Dermatopontin in Bone Marrow Extracellular Matrix Regulates Adherence but Is Dispensable for Murine Hematopoietic Cell Maintenance. Stem Cell Reports 9:770-778
Smith, Michelle J; Reichenbach, Dawn K; Parker, Sarah L et al. (2017) T cell progenitor therapy-facilitated thymopoiesis depends upon thymic input and continued thymic microenvironment interaction. JCI Insight 2:
Angelos, Mathew G; Ruh, Paige N; Webber, Beau R et al. (2017) Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells. Blood 129:3428-3439
Pomeroy, E J; Lee, L A; Lee, R D W et al. (2017) Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia. Oncogene 36:3263-3273
Webber, Beau R; O'Connor, Kyle T; McElmurry, Ron T et al. (2017) Rapid generation of Col7a1-/- mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells. Lab Invest 97:1218-1224
Matta, B M; Reichenbach, D K; Blazar, B R et al. (2017) Alarmins and Their Receptors as Modulators and Indicators of Alloimmune Responses. Am J Transplant 17:320-327
Skvarova Kramarzova, Karolina; Osborn, Mark J; Webber, Beau R et al. (2017) CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells. Int J Mol Sci 18:

Showing the most recent 10 out of 102 publications